Mattias Aine

Dr. Mattias Aine


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in European Urology
Verified
Journal Article
Open access
AKAurélie Kamoun
Aurélie Kamoun
ARAurélien de Reyniès
Aurélien de Reyniès
YAYves Allory
Yves Allory
GSGottfrid Sjödahl
Gottfrid Sjödahl
ARA. Gordon Robertson
A. Gordon Robertson
JWJohn Weinstein
John Weinstein
Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting.

14 June 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GSGottfrid Sjödahl
Gottfrid Sjödahl
MLMartin Lauss
Martin Lauss
KLKristina Lövgren
Kristina Lövgren
GCGunilla Chebil
Gunilla Chebil
SGSigurdur Gudjonsson
Sigurdur Gudjonsson
MHMattias Höglund
Mattias Höglund
Purpose: Even though urothelial cancer is the fourth most common tumor type among males, progress in treatment has been scarce. A problem in day-to-day clinical practice is that precise assessment of individual tumors is still fairly uncertain; consequently efforts have been undertaken to complement tumor evaluation with molecular biomarkers. An extension of this approach would be to base tumor classification primarily on molecular features. Here, we present a molecular taxonomy for urothelial carcinoma based on integrated genomics. Experimental Design: We use gene expression profiles from 308 tumor cases to define five major urothelial carcinoma subtypes: urobasal A, genomically unstable, urobasal B, squamous cell carcinoma like, and an infiltrated class of tumors. Tumor subtypes were validated in three independent publically available data sets. The expression of 11 key genes was validated at the protein level by immunohistochemistry. Results: The subtypes show distinct clinical outcomes and differ with respect to expression of cell-cycle genes, receptor tyrosine kinases particularly FGFR3, ERBB2, and EGFR, cytokeratins, and cell adhesion genes, as well as with respect to FGFR3, PIK3CA, and TP53 mutation frequency. The molecular subtypes cut across pathologic classification, and class-defining gene signatures show coordinated expression irrespective of pathologic stage and grade, suggesting the molecular phenotypes as intrinsic properties of the tumors. Available data indicate that susceptibility to specific drugs is more likely to be associated with the molecular stratification than with pathologic classification. Conclusions: We anticipate that the molecular taxonomy will be useful in future clinical investigations. Clin Cancer Res; 18(12); 3377–86. ©2012 AACR.

1 July 2016 in Cancer Cell
Verified
Journal Article
Closed access
JHJakob Hedegaard
Jakob Hedegaard
PLPhilippe Lamy
Philippe Lamy
INIver Nordentoft
Iver Nordentoft
FAFerran Algaba
Ferran Algaba
SHSøren Høyer
Søren Høyer
LDLars Dyrskjøt
Lars Dyrskjøt

1 September 2017 in European Urology
Verified
Journal Article
Closed access
WCWoonyoung Choi
Woonyoung Choi
AOAndrea Ochoa
Andrea Ochoa
DMDavid J. McConkey
David J. McConkey
MAMattias Aine
Mattias Aine
MHMattias Höglund
Mattias Höglund
SLSeth P. Lerner
Seth P. Lerner

1 September 2013 in The American Journal of Pathology
Verified
Journal Article
Open access
GSGottfrid Sjödahl
Gottfrid Sjödahl
KLKristina Lövgren
Kristina Lövgren
MLMartin Lauss
Martin Lauss
OPOliver Patschan
Oliver Patschan
SGSigurdur Gudjonsson
Sigurdur Gudjonsson
MHMattias Höglund
Mattias Höglund
We recently defined molecular subtypes of urothelial carcinomas according to whole genome gene expression. Herein we describe molecular pathologic characterization of the subtypes using 20 genes and IHC of 237 tumors. In addition to differences in expression levels, the subtypes show important differences in stratification of protein expression. The selected genes included biological features central to bladder cancer biology, eg, cell cycle activity, cellular architecture, cell-cell interactions, and key receptor tyrosine kinases. We show that the urobasal (Uro) A subtype shares features with normal urothelium such as keratin 5 (KRT5), P-cadherin (P-Cad), and epidermal growth factor receptor (EGFR) expression confined to basal cells, and cell cycle activity (CCNB1) restricted to the tumor-stroma interface. In contrast, the squamous cell cancer-like (SCCL) subtype uniformly expresses KRT5, P-Cad, EGFR, KRT14, and cell cycle genes throughout the tumor parenchyma. The genomically unstable subtype shows proliferation throughout the tumor parenchyma and high ERBB2 and E-Cad expression but absence of KRT5, P-Cad, and EGFR expression. UroB tumors demonstrate features shared by both UroA and SCCL subtypes. A major transition in tumor progression seems to be loss of dependency of stromal interaction for proliferation. We present a simple IHC/histology-based classifier that is easy to implement as a standard pathologic evaluation to differentiate the three major subtypes: urobasal, genomically unstable, and SCCL. These three major subtypes exhibit important prognostic differences.

1 November 2015 in European Urology
Verified
Journal Article
Closed access
OPOliver Patschan
Oliver Patschan
GSGottfrid Sjödahl
Gottfrid Sjödahl
GCGunilla Chebil
Gunilla Chebil
KLKristina Lövgren
Kristina Lövgren
MLMartin Lauss
Martin Lauss
MHMattias Höglund
Mattias Höglund